We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




New Gene Linked to Key Heart Attack Risk Factor

By LabMedica International staff writers
Posted on 26 Mar 2014
A previously unrecognized gene variation that makes humans have healthier blood lipid levels and reduced risk of heart attacks has been found. More...


The region of DNA where it was located had been implicated as being important in controlling blood lipid levels, but although this DNA region had many genes, none of them had any obvious link to blood lipid levels.

A team of scientists from the University of Michigan (Ann Arbor, Michigan, USA) and the Norwegian University of Science and Technology (Levanger, Norway) scanned the genetic information available from a biobank of a large number of Norwegians, focusing on variations in genes that change the way proteins function. Most of what they found turned out to be already known to affect cholesterol levels and other blood lipids. Total cholesterol (TC), high density lipid (HDL) cholesterol and triglycerides were measured by an enzymatic colorimetric method using the 911 Auto-Analyzer (Hitachi; Tokyo, Japan).

Genotyping of 5,771 individuals was performed using the Human Exome BeadChips (Illumina; San Diego, CA, USA) using their Infinium HD ultra protocol. The exome array includes 247,870 markers focused on protein-altering variants. Low-pass whole-genome sequencing was performed with exome enrichment on 76 cases with myocardial infarction (MI) and 76 controls using Illumina’s Hi-Seq 2500 ultra-high-throughput sequencing system. In a minority of the Norwegians who carried a particular change in a gene, blood lipid levels were much healthier and they had a lower rate of heart attack. This gene, known as Transmembrane 6 Superfamily Member 2 (TM6SF2), may also be involved in regulating lipid levels in the liver.

Cristen Willer, PhD, the senior author of the paper, said, “Cardiovascular disease presents such a huge impact on people's lives that we should leave no stone unturned in the search for the genes that cause heart attack. While genetic studies that focused on common variations may explain as much as 30% of the genetic component of lipid disorders, we still don't know where the rest of the genetic risk comes from. This approach of focusing on protein-changing variation may help us zero in on new genes faster.” The study was published on March 16, 2014, in the journal Nature Genetics.

Related Links:

University of Michigan
Norwegian University of Science and Technology
Illumina



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.